Theseus Pharmaceuticals Analysis
Theseus Pharmaceuticals is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Theseus Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Theseus Pharmaceuticals is worth, separate from its market price. There are two main types of Theseus Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Theseus Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Theseus Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Theseus Stock trading window is adjusted to America/New York timezone.
Theseus |
Theseus Stock Analysis Notes
About 93.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.81. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Theseus Pharmaceuticals has Price/Earnings (P/E) ratio of 737.67. The entity recorded a loss per share of 1.34. The firm last dividend was issued on the September 8, 2015. Theseus Pharmaceuticals had 1241:1000 split on the June 3, 2014. Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Theseus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Theseus Pharmaceuticals contact Timothy Clackson at 857 400 9491 or learn more at https://theseusrx.com.Theseus Pharmaceuticals Investment Alerts
| Theseus Pharmaceuticals is not yet fully synchronised with the market data | |
| Theseus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Theseus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (56.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Theseus Pharmaceuticals currently holds about 212.43 M in cash with (49.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.55. | |
| Over 93.0% of the company shares are owned by institutional investors |
Theseus Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Theseus Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Theseus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 181.28 M.Theseus Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theseus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theseus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theseus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
William Shakespeare over a year ago Exercise or conversion by William Shakespeare of 251084 shares of Theseus Pharmaceuticals subject to Rule 16b-3 | ||
Foresite Capital Management V Llc over a year ago Purchase by Foresite Capital Management V Llc of 176550 shares of Theseus Pharmaceuticals | ||
Dukes Iain D over a year ago Acquisition by Dukes Iain D of 3250 shares of Theseus Pharmaceuticals subject to Rule 16b-3 | ||
Kerstein David over a year ago Acquisition by Kerstein David of 17500 shares of Theseus Pharmaceuticals subject to Rule 16b-3 | ||
Kerstein David over a year ago Acquisition by Kerstein David of 105000 shares of Theseus Pharmaceuticals subject to Rule 16b-3 |
Theseus Pharmaceuticals Outstanding Bonds
Theseus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Theseus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Theseus bonds can be classified according to their maturity, which is the date when Theseus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Theseus Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |